NEW YORK (GenomeWeb News) – Illumina said this week that Robert Epstein has joined its board of directors. Epstein formerly was chief R&D officer and president of Medco-UBC, and he was Medco’s chief medical officer for 13 years.
He also served as president of the International Society of Pharmacoeconomics and Outcomes Research, and he was on the board of directors of the Drug Information Association and the International Society of Quality of Life.
Vermillion has tapped Bruce Huebner to be interim CEO, taking over for Gail Page, who will serve as a strategic advisor to the company. The company’s board has formed a succession committee and retained an executive search firm to find a new CEO to fill the post long-term.
Huebner will continue to serve on the company’s board of directors as he handles the added interim-CEO duties. His executive management experience includes stints as president of Osmetech, president and CEO of Nanogen, and as executive VP and chief operating officer at Gen-Probe.
Erin O'Shea has been elected VP and chief scientific officer of the Howard Hughes Medical Institute. She will begin her duties part-time at the start of 2013 and will transition into them full-time in July.
For the past seven years, O'Shea has been director of the Harvard Faculty of Arts and Sciences Center for Systems Biology, and she is a professor of molecular and cellular biology, chemistry, and chemical biology at Harvard. Before she joined Harvard, O'Shea was an HHMI investigator at the University of California, San Francisco.
DiagnoCure has named Jacques Simoneau and Andrew Sheldon to serve on its board of directors. Simoneau is president and CEO of Gestion Univalor, and before that he was executive VP of investments of the Business Development Bank of Canada, where he was responsible for venture capital and financing, and he was president and CEO of Hydro-Quebec CapiTech.
Sheldon has been president and CEO of Medicago for nearly a decade, and he has 30 years of experience in the pharmaceutical industry. Simoneau has agreed to join and to chair the Audit and Risk Management Committee.
The company said that the new appointments happened after Paul Gobeil, Alain Michel, and Mario Thomas retired from the board.
Bioseparation and proteomics technologies company Nusep said this week that Iain Sorrell, David Roffe, and Ward Westcott will all step down from the company's board as of Nov. 30. The company said it plans to add new board members with new skill sets.
Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.